| |
Researchers have been using BioIVT’s HEPATOPAC as a long-term functional in vitro model for compound screening, toxicity evaluation and assessment of gene regulation. View Research >> 
|
|
Today’s Big NewsJun 27, 2024 |
| By Gabrielle Masson Novo Nordisk’s late-stage kidney disease drug failed to evoke significant changes in systolic blood pressure, a loss that will cost the Danish drugmaker more than $800 million. |
|
|
|
By Gabrielle Masson 2seventy bio has split again, this time sending its hemophilia A program and related staff to Novo Nordisk. |
By Gabrielle Masson AbbVie is embracing summer’s heat, cranking up the M&A dial with the acquisition of inflammatory disease-focused Celsius Therapeutics for $250 million cash. |
Sponsored by Cardinal Health CGT companies should consider developing a market access strategy early in clinical development, ideally more than three years prior to launch. |
By Nick Paul Taylor Silence Therapeutics has spoken up about its phase 1 polycythemia vera clinical trial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda. |
By Helen Floersh Six months after its due date, the FDA’s draft guidance for clinical trial diversity is finally here. The agency issued a new outline of its proposed requirements for the racial and ethnic diversity action plans that will eventually be mandatory components of studies on drugs, devices and other medical products. |
By James Waldron CalciMedica said it is “moving quickly” to take Auxora into phase 3 after the calcium release-activated calcium channel inhibitor was shown to reduce the time before solid food could be consumed by a subgroup of patients with hyperinflamed pancreatitis. |
By Angus Liu In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody drug conjugate patritumab deruxtecan. |
By Kevin Dunleavy Verona Pharma has earned an FDA approval for Ohtuvayre, a potential blockbuster with a novel mechanism of action, to treat patients with chronic obstructive pulmonary disorder. It is the first novel treatment advancement in the indication in more than a decade. |
By Zoey Becker The vaccines are now recommended for adults aged 75 years and older and those aged 60 to 74 with a higher risk of severe disease. Previously, all adults aged 60 and older were advised for vaccination. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing. |
|
|---|
|
|
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
